Fulgent Genetics, Inc. FLGT Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers SquibbBMY

$912M+0.6%

AzentaAZTA

——

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s available for sale securities debt securities current?: Fulgent Genetics, Inc. (FLGT) reported available for sale securities debt securities current of $252.9M in Q1 2026.
What is the long-term trend for Fulgent Genetics, Inc.'s available for sale securities debt securities current?: Over 2 years (2020 to 2025), Fulgent Genetics, Inc.'s available for sale securities debt securities current has grown at a 16.1% compound annual growth rate (CAGR), from $211.94M to $285.88M.